From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can ...

A crash course on the bubble itself, including therapeutic areas most affected. This column marks the first of a six-part series on “Popping the Gross-to-Net (GTN) Bubble" in the pharmaceutical ...

Embedding access tools at prescribing reduces manual enrollment, portal switching, and late activation, enabling faster ...

Shawn Seamans, Chief Commercial Officer, CoverMyMeds | Authors | Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking ...

Lilly will pay $6.75 per share (~26% premium), totaling $2.8 billion upfront with up to $1 billion milestone-based consideration, and expects closure in Q3 2026. Federal acceleration of psychedelic ...

Brent Wilhelm of Cencora discusses why available inventory still leads to shortages, and how tighter distributor-manufacturer integration and AI could close the gap. In part 1 of a 3-part interview ...

In this Dedicated Dialogue episode, Adam Fox, Chief Quality & Regulatory Affairs Officer of Cryoport Systems, explores how escalating regulatory expectations and patient-centric risk considerations ...

Episode 1 of Supply Chain Signal breaks down the FDA's PreCheck pilot, the US Section 301 probe into German drug pricing, and CMS's move to make Medicare drug price negotiation permanent. The debut ...

Pairing Tennr referral intake and documentation automation with TailorMed affordability tooling is designed to surface access barriers earlier and shorten time-to-therapy for infusion and specialty ...

Tech-enabled pharmacies reflect the reality of the GLP-1 landscape: patient success depends on more than a prescription. With ...